The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
about
FH535 Suppresses Osteosarcoma Growth In Vitro and Inhibits Wnt Signaling through TankyrasesmTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)Efflux inhibition by IWR-1-endo confers sensitivity to doxorubicin effects in osteosarcoma cells.Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
P2860
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The novel tankyrase inhibitor ...... ase and irinotecan resistance.
@en
The novel tankyrase inhibitor
@nl
type
label
The novel tankyrase inhibitor ...... ase and irinotecan resistance.
@en
The novel tankyrase inhibitor
@nl
prefLabel
The novel tankyrase inhibitor ...... ase and irinotecan resistance.
@en
The novel tankyrase inhibitor
@nl
P2093
P2860
P356
P1433
P1476
The novel tankyrase inhibitor ...... ase and irinotecan resistance.
@en
P2093
Alwin G Schuller
Anna Capasso
Anna Nguyen
Anna Schreiber
Dexiang Gao
Guoliang Wang
John J Arcaroli
Justin Greene
Kevin S Quackenbush
P2860
P304
28273-28285
P356
10.18632/ONCOTARGET.8626
P407
P577
2016-04-07T00:00:00Z